Landscape of tumor mutational burden-high (TMB-high) and its correlation with immune checkpoint inhibitor biomarkers in gynecologic tumors

被引：0
|
作者：
Huang, Richard [1 ]
Lin, Douglas [1 ]
Danziger, Natalie [1 ]
Williams, Erik [2 ]
Elvin, Julia [1 ]
机构：
[1] Fdn Med Inc, Raleigh, NC USA
[2] UCSF & Fdn Med, San Francisco, CA USA
来源：
GYNECOLOGIC ONCOLOGY | 2021年 / 162卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
371
引用
收藏
页码：S196 / S196
页数：1
相关论文
共 50 条
  • [31] DEEP, DURABLE RESPONSE TO PD-1 INHIBITOR MONOTHERAPY IN MICROSATELLITE-STABLE, TUMOR MUTATIONAL BURDEN-HIGH COLORECTAL CANCER
    Schellenberg, Samuel
    Kim, Leeseul
    Chae, Young Kwang
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A661 - A661
  • [32] Penile squamous cell carcinoma with high and very high tumor mutational burden (TMB): A genomic landscape and "real-world" clinical outcome study
    Jacob, J. M.
    Spiess, P.
    Padua, T. C. D.
    Li, R.
    Grivas, P.
    Huang, R.
    Lin, D. I.
    Danziger, N. A.
    Ross, J. S.
    Li, G.
    Graf, R. P.
    Pavlick, D. C.
    Basnet, A.
    Bratslavsky, G.
    Necchi, A.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S506 - S506
  • [33] Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
    Valero, Cristina
    Lee, Mark
    Hoen, Douglas
    Weiss, Kate
    Kelly, Daniel W.
    Adusumilli, Prasad S.
    Paik, Paul K.
    Plitas, George
    Ladanyi, Marc
    Postow, Michael A.
    Ariyan, Charlotte E.
    Shoushtari, Alexander N.
    Balachandran, Vinod P.
    Hakimi, A. Ari
    Crago, Aimee M.
    Roche, Kara C. Long
    Smith, J. Joshua
    Ganly, Ian
    Wong, Richard J.
    Patel, Snehal G.
    Shah, Jatin P.
    Lee, Nancy Y.
    Riaz, Nadeem
    Wang, Jingming
    Zehir, Ahmet
    Berger, Michael F.
    Chan, Timothy A.
    Seshan, Venkatraman E.
    Morris, Luc G. T.
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [34] Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
    Cristina Valero
    Mark Lee
    Douglas Hoen
    Kate Weiss
    Daniel W. Kelly
    Prasad S. Adusumilli
    Paul K. Paik
    George Plitas
    Marc Ladanyi
    Michael A. Postow
    Charlotte E. Ariyan
    Alexander N. Shoushtari
    Vinod P. Balachandran
    A. Ari Hakimi
    Aimee M. Crago
    Kara C. Long Roche
    J. Joshua Smith
    Ian Ganly
    Richard J. Wong
    Snehal G. Patel
    Jatin P. Shah
    Nancy Y. Lee
    Nadeem Riaz
    Jingming Wang
    Ahmet Zehir
    Michael F. Berger
    Timothy A. Chan
    Venkatraman E. Seshan
    Luc G. T. Morris
    [J]. Nature Communications, 12
  • [35] Tissue tumor mutational burden (TMB) as a biomarker of efficacy with immune checkpoint inhibitors (ICI) in metastatic gastrointestinal (mGI) cancers.
    Lentz, Robert William
    Friedrich, Tyler
    Hu, Junxiao
    Leal, Alexis Diane
    Kim, Sunnie S.
    Davis, S. Lindsey
    Purcell, Tom
    Messersmith, Wells A.
    Lieu, Christopher Hanyoung
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB).
    Florou, Vaia
    Floudas, Charalampos S.
    Maoz, Asaf
    Naqash, Abdul Rafeh
    Hildebrand, Gregory
    Sokol, Ethan
    Frampton, Garrett M.
    Puri, Sonam
    Swami, Umang
    Wilky, Breelyn A.
    Hosein, Peter Joel
    Trent, Jonathan C.
    Lopes, Gilberto
    Park, Wungki
    Garrido-Laguna, Ignacio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors
    Shinojima, Naoki
    Ozono, Kazutaka
    Yamamoto, Haruaki
    Abe, Sakiko
    Sasaki, Rumi
    Tomita, Yusuke
    Kai, Azusa
    Mori, Ryosuke
    Yamamoto, Takahiro
    Uekawa, Ken
    Matsui, Hirotaka
    Nosaka, Kisato
    Matsuzaki, Hiroaki
    Komohara, Yoshihiro
    Mikami, Yoshiki
    Mukasa, Akitake
    [J]. BRAIN TUMOR PATHOLOGY, 2023, 40 (03) : 185 - 190
  • [38] Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
    Schrock, A. B.
    Ouyang, C.
    Sandhu, J.
    Sokol, E.
    Jin, D.
    Ross, J. S.
    Miller, A.
    Lim, D.
    Amanam, I
    Chao, J.
    Catenacci, D.
    Cho, M.
    Braiteh, F.
    Klempner, S. J.
    Ali, S. M.
    Fakih, M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (07) : 1096 - 1103
  • [39] Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors
    Naoki Shinojima
    Kazutaka Ozono
    Haruaki Yamamoto
    Sakiko Abe
    Rumi Sasaki
    Yusuke Tomita
    Azusa Kai
    Ryosuke Mori
    Takahiro Yamamoto
    Ken Uekawa
    Hirotaka Matsui
    Kisato Nosaka
    Hiroaki Matsuzaki
    Yoshihiro Komohara
    Yoshiki Mikami
    Akitake Mukasa
    [J]. Brain Tumor Pathology, 2023, 40 : 185 - 190
  • [40] Microsatellite instability (MSI), mismatch repair (MMR), and tumor mutational burden (TMB) as predictive biomarkers for immune checkpoint inhibitor (ICI) effectiveness in real-world patients with metastatic colorectal cancer (mCRC).
    Ellis, Haley
    Klempner, Samuel J.
    Quintanilha, Julia C. F. C. F.
    Myer, Parvathi
    Lin, Douglas I.
    Panarelli, Nicole
    Fisher, Virginia
    Li, Gerald
    Huang, Richard S. P.
    Ross, Jeffrey S.
    Oxnard, Geoffrey R.
    Graf, Ryon
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 46 - 46
12345